Finoriq research workspace
REGENERON PHARMACEUTICALS, INC. (REGN) SEC Filings & Filing Highlights
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes. Review REGN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
- Company
- REGENERON PHARMACEUTICALS, INC. (REGN)
- Ticker
- REGN
- Market Cap
- $70.7B
- Latest Price
- $674.06
- Industry
- Biotech & Pharma
REGENERON PHARMACEUTICALS, INC. (REGN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for REGENERON PHARMACEUTICALS, INC. (REGN).
| Event | Form | Date |
|---|---|---|
| Note Regarding Forward-Looking StatementsRegeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U... | 8-K2.02 | 2026-07-06 |
| At the 2026 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. held on June 12,...At the 2026 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) held on June 12, 2026, Regener... | 8-K5.07 | 2026-06-17 |
| Regeneron Reports First Quarter 2026 Financial and Operating ResultsRegeneron Reports First Quarter 2026 Financial and Operating Results | 8-K2.02 | 2026-04-29 |
| Note Regarding Forward-Looking StatementsRegeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U... | 8-K2.02 | 2026-04-08 |
| Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsRegeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | 8-K2.02 | 2026-01-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.